Key Takeaways Hologic's Diagnostics revenue rose in Q4 on stronger U.S. molecular testing and 4.4% organic growth.Molecular Diagnostics led gains, fueled by Hologic's BV CV/TV and Panther Fusion assay momentum.HOLX broadened its Diagnostics lineup with EU expansion for Genius and new Panther Fusion assays.Hologic (HOLX) offers a wide range of diagnostic products to help in the screening and diagnosis of human disease. Although the performance of the Diagnostics segment in recent quarters has been impacted b ...